- Distinguished economist and former CEO of Ecopetrol,
Colombia's largest corporation and
the fourth largest Latin America
oil and gas producer included in the Fortune Global 500
- Internationally recognized advocate for the cannabis industry
as a driver of change for the Latam economy
- Adds proven economic and international business experience to
boost the global growth of the Khiron business model
- Company to discuss Q3 2020 financials and host webcast on
Tuesday, December 1st
TORONTO, Nov. 30, 2020 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, announces that Mr. Juan Carlos Echeverry has been appointed to the
Board of Directors of the Company, effective immediately. Mr.
Echeverry brings extensive corporate, academic and macroeconomic
experience, serving as Colombia's
Minister of Finance from 2010 to 2012 and as the CEO and President
of Ecopetrol from 2015 to 2017.
"We are very pleased to welcome Juan
Carlos Echeverry to our Board as an independent director.
His exceptional economic experience and understanding of the
cannabis space in Latin America
will be an invaluable asset as we continue to execute on our sales
strategy in Latin American and global markets," comments
Alvaro Torres, Khiron CEO and
Director.
Juan Carlos Echeverry is a Colombian economist and a
recognized advocate for medical cannabis as an economic catalyst
for the region. Mr. Echeverry served as Colombia's Minister of Economic Planning
from 2000 to 2002 and was the representative for Colombia before the Inter-American Development
Bank.
From 2015 to 2017, Mr. Echeverry served as CEO and President of
Ecopetrol, Colombia's largest
Corporation and the fourth largest Latin American oil and gas
producer included in the Fortune Global 500. Having steered the
company through a period of high volatility, Mr. Echeverry is
credited with achieving efficiencies in costs and production, while
developing production, reserves, and international
partnerships.
Mr. Echeverry is a founding Partner of EConcept, a Bogotá based
consultancy, and partner of Global Source, a New York based consultancy with presence in 21
emerging economies, and a former Dean of Economics at Universidad
de los Andes (Bogotá). He is also a past visiting professor at IE
Business School in Madrid, Spain,
and Georgetown University in
Washington DC. Mr. Echeverry has a
Ph.D. in Economics from New York
University, a Diploma from Kiel Institute of World
Economics and a B.A. in Economics from Universidad de los
Andes.
"Medical cannabis represents a remarkable opportunity for
Colombia. World markets are
expanding, and Colombia has
production, R&D and export capabilities that have
billion-dollar potential for this country. Alvaro and the Khiron
team have proven to be leaders in establishing the Colombian
market, and I look forward to participating as a Board member in
their continued global growth," comments Mr. Echeverry.
Webcast and Q&A
Khiron invites individual and
institutional investors, as well as advisors and analysts, to
attend a webcast and Q&A to discuss the Company's Q3 2020
financial statements and further activities.
DATE: Tuesday, December 1st,
2020
TIME: 10:00am EST/7:00am PST
PRESENTERS: Alvaro Torres,
CEO and Director, Joel Friedman,
CFO, and Chris Naprawa, Chairman
FORMAT: Live 30 minutes presentation and Q&A session
REGISTER LINK:
https://event.on24.com/wcc/r/2819768/9328DB919FFBB024F2CF5F4F5119285E
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the
leading cannabis company in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Peru and has a presence in Mexico, Uruguay, UK, Spain and also in Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage and patient-oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with KuidaTM
now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/juan-carlos-echeverry-former-colombian-minister-of-finance-and-former-ceo-of-colombias-largest-company-joins-khiron-board-of-directors-301181446.html
SOURCE Khiron Life Sciences Corp.